siRNA Against URAT1 — Discovery-Engine Output, Kidney-Tropic Modality¶
Status: scope-page (2026-05-05). Dedicated page formalizing the kidney-tropic siRNA / URAT1 vector flagged in modality-chokepoint-matrix.md as the cleanest "elegant solution" in the matrix's open-exploration queue. Phase 2 follow-ups (lit scans on conjugate chemistry, commercial / clinical landscape, regulatory path; comp-009 target site selection; falsification card H03; comparative analysis vs. existing small-molecule URAT1 inhibitors) are tracked in Open Follow-Ups.
Why this page exists¶
modality-chokepoint-matrix.md ranks kidney-tropic siRNA against URAT1 as the #1 open exploration vector — "the cleanest 'elegant solution' in the entire matrix." The 2026-05-05 sweep Open Question / Priority Action #3 formalizes this as a dedicated page.
The mission framing (per Brian's 2026-05-05 reframe): Open Enzyme is a research project to solve gout via every available modality, fully open. The koji chassis is its first and primary chassis expression — but it is not the entire mission. This page is the second peer-track exploration vector developed under that reframe, alongside engineered-lbp-chassis.md (which formalized engineered Live Biotherapeutic Products as a peer track for the gut-resident butyrate / colonization vector).
This vector is fundamentally non-fermentable. Kidney-tropic siRNA biologics require synthetic oligonucleotide chemistry, conjugate or LNP formulation, IV / subcutaneous delivery, and the FDA biologic regulatory pathway. There is no microbial chassis that produces a kidney-tropic siRNA conjugate. This vector therefore lives in the discovery-engine output half of Open Enzyme's two-output architecture (per open-enzyme-vision.md §2.2 "The repurposing surface" — non-microbial mechanism candidates the platform identifies but does not itself manufacture). Parallel to how zileuton, disulfiram, and avacopan appear in the OE corpus as repurposing candidates (small-molecule pharma drugs the platform recommends but does not engineer), siRNA against URAT1 is positioned as a discovery-engine output the platform scopes, characterizes, and publishes — for partner companies, academic groups, or future spinouts to actually develop.
What URAT1 is and why silencing it matters¶
URAT1 (SLC22A12; chromosome 11) is a urate / organic anion exchanger expressed on the apical membrane of the renal proximal tubule. Its job: reabsorb uric acid from the tubular lumen back into the blood. Per gout-pathophysiology.md:
- ~70% of daily uric acid elimination is renal (the rest is gut, primarily via ABCG2 — the chassis the koji platform engineers around)
- URAT1 reabsorbs ~90% of filtered urate — the dominant renal-side urate-handling lever
- Under-excreter gout (the majority phenotype, ~80% of gout patients) is largely a URAT1-overactivity / ABCG2-underactivity phenotype
- Brian's hyperuricemia is in this under-excreter category, which is why URAT1 is named in
androgen-urate-axis.mdas one of the two transporters androgens modulate (URAT1 ↑ on T; ABCG2 ↓ on T)
Why sequence-specific knockdown is mechanistically cleaner than small-molecule inhibition:
The existing URAT1 inhibitor class (probenecid, lesinurad, dotinurad, pozdeutinurad / AR882) works by competitive binding at the URAT1 substrate site. This is well-validated pharmacology — but the historical poster child for the class, benzbromarone, was withdrawn in many markets after fulminant hepatotoxicity reports (FDA never approved it). The hepatotoxicity is not URAT1-on-target; it's an off-target metabolite (benzbromarone reactive metabolites covalently bind hepatic proteins). This is a small-molecule chemistry problem, not a URAT1 biology problem. siRNA against URAT1 mRNA eliminates the off-target metabolite class entirely — there is no benzbromarone-class metabolite in an oligonucleotide therapeutic. Sequence specificity (~21 nt match to URAT1 mRNA, no other human transcript) gives a categorically different off-target safety profile.
Additional advantages over small-molecule URAT1 inhibitors: - Durability: siRNA effect persists weeks to months after a single dose (vs. daily oral pills for the small-molecule class). Inclisiran demonstrates ~6-month effect from a single subcutaneous dose for PCSK9 silencing. - Adherence: quarterly subcutaneous injection vs. daily-pill compliance burden. - Sex-hormone interaction: siRNA knockdown is hormone-independent, so it would work as well in clomid / TRT / endogenous-T-elevated patients (where URAT1 is upregulated) as in baseline patients. This is the same advantage the LBP butyrate vector has over koji-delivered uricase: it's genotype- and hormone-axis-agnostic.
Dose-ceiling constraint from W258X homozygote phenotype. The human-genetic safety case for partial URAT1 knockdown rests on W258X heterozygotes (Japanese allele frequency ~2.23–2.55%; Korean ~0.9–1.4% per Ichida 2024 J-STAGE review and the P0-2 two-model read; see gout-genetic-variants.md §"URAT1 W258X"). W258X homozygotes have a clean knockout phenotype: serum uric acid 0.75 mg/dL (Sakiyama 2021 PMID 34440216, n=30,685 Japanese males) — ~12% of population mean. Ichida 2024 estimates exercise-induced acute kidney injury in ~6–7% of renal-hypouricemia patients overall, but homozygote-vs-heterozygote lifetime risk remains unquantified. Implication: target ≤50% knockdown ceiling to avoid recapitulating homozygote-equivalent phenotype under exercise stress. This is a load-bearing dosage constraint that should be encoded in any siRNA dose-finding study design.
The hard part: kidney-tropic delivery¶
siRNA delivery is the platform's central engineering problem, and kidney-tropic delivery specifically is the hardest variant. The platform-defining successes in approved siRNA biologics are all liver-targeted:
- Inclisiran (Alnylam / Novartis, FDA approved 2021): GalNAc-conjugated siRNA against PCSK9. GalNAc binds the asialoglycoprotein receptor (ASGPR), which is expressed almost exclusively on hepatocytes. The conjugate is ~95% liver-localized after subcutaneous injection. Effect: ~50% LDL-C reduction sustained for ~6 months per single dose.
- Patisiran (Alnylam, FDA approved 2018): LNP-delivered siRNA against TTR for transthyretin amyloidosis. LNPs accumulate in liver via apoE-mediated hepatocyte uptake.
- Vutrisiran, lumasiran, givosiran, etc.: all liver-targeted, all GalNAc-ASGPR or LNP-apoE.
Kidneys lack ASGPR. The GalNAc trick does not transfer. There is no FDA-approved kidney-tropic siRNA biologic. The delivery chemistry is the gating engineering problem.
Active research-class kidney-tropic delivery candidates (all preclinical or early clinical for non-gout indications):
- Megalin-binding conjugates. Megalin (LRP2) is a large multi-ligand endocytic receptor enriched on the apical membrane of the renal proximal tubule — exactly the cell type expressing URAT1. Megalin natively endocytoses albumin, vitamin-binding proteins, and several pharmacologically-relevant ligands. Megalin-binding peptide conjugates have been demonstrated preclinically (small peptides 8–15 aa derived from megalin's natural ligands). Active research class; no FDA approvals yet.
- Cyclodextrin-based polymer (CDP) nanoparticles. Sirnaomics and Calando Pharmaceuticals have CDP-based siRNA delivery platforms with documented kidney accumulation (CDP particles are renally cleared and accumulate in proximal tubule en route). CALAA-01 (Calando, since discontinued) was the first systemically-administered targeted siRNA in human trials.
- Kidney-cortex-selective LNPs. LNP composition (lipid head-group charge, PEGylation, particle size) can shift biodistribution. Active formulation chemistry — Acuitas, Genevant, others have programs.
- Aptamer-siRNA chimeras. RNA aptamer selected for kidney-cell-surface receptor binding fused to siRNA. Research stage; no clinical programs for kidney-tropic gout indication.
The honest assessment: kidney-tropic conjugate chemistry is roughly where GalNAc-ASGPR was in 2008 — mechanistically promising, multiple competing approaches, no clinical proof-of-concept yet for any kidney indication. First-in-human kidney-tropic siRNA for any indication is probably 3–5 years out; first-for-gout is later. This is a long-horizon vector. It does not compete with pozdeutinurad's 2026 NDA timeline; it competes with whatever the next-generation post-pozdeutinurad URAT1 modulator looks like in the early 2030s.
Competitive landscape — existing URAT1 modulators¶
| Drug | Class | Status | Note |
|---|---|---|---|
| Probenecid | Uricosuric, URAT1 inhibitor | Approved | Off-patent, decades-old, used clinically |
| Lesinurad | Selective URAT1 inhibitor | Approved (combo with allopurinol; standalone discontinued) | Boxed warning for renal events |
| Dotinurad (URECE) | Selective URAT1 inhibitor | Approved in Japan, China, Thailand, Philippines | Not US-approved |
| Pozdeutinurad (AR882) | Next-gen selective URAT1 inhibitor | Phase 3 | REDUCE 1 & 2 fully enrolled; Arthrosi NDA planned 2026 |
| HNW005 | Dual NLRP3 + URAT1 inhibitor | Preclinical | Single molecule, both targets |
| Benzbromarone | URAT1 inhibitor (historical) | Withdrawn in many markets | Fulminant hepatotoxicity; the cautionary tale that motivates the siRNA approach |
siRNA's competitive position: not a near-term replacement for the small-molecule class (pozdeutinurad will likely launch in 2026–2027 with strong efficacy and a clean safety profile relative to benzbromarone). siRNA's distinctive value is the durability + sequence-specificity + hormone-independence combination at a 5–10 year horizon — the patient profile where: (a) daily-pill adherence is the bottleneck (quarterly injection wins); (b) any small-molecule off-target profile is unacceptable (refractory + hepatic-impaired patients); © hormone-axis modulation makes pill-class efficacy unreliable (clomid / TRT users where URAT1 is upregulated and the inhibitor IC50 needs to be re-met against elevated transporter density).
This is the same logic as engineered LBPs (peer-track to koji) — both modalities serve a different patient population than the platform's primary chassis, on a different timeline and regulatory path, complementing rather than competing.
Position in the Open Enzyme platform — discovery-engine output¶
Per open-enzyme-vision.md §2.2 ("The repurposing surface"), Open Enzyme operates on a two-output architecture:
- The discovery engine — chokepoint-based methodology for mapping every vector that causes, treats, or mitigates a target disease. Outputs include the cascade maps, the chokepoint inventory, and the repurposing surface (FDA-approved drugs that hit relevant chokepoints but were never clinically tested for the target disease, e.g., zileuton for 5-LOX, disulfiram for NLRP3, avacopan for C5aR1).
- The open-source strain library — engineered koji / yeast strains the platform itself manufactures and distributes. The koji endgame strain (
koji-endgame-strain.md) is the canonical example.
siRNA against URAT1 is firmly a discovery-engine output, not a strain-library output. The platform identifies the mechanism, scopes the modality, characterizes the design space, and publishes — but does not itself manufacture siRNA biologics. Partners (academic groups working on kidney-tropic delivery; existing siRNA pharma like Alnylam, Arrowhead Pharmaceuticals, Dicerna / Novo Nordisk; or future Open Enzyme spinouts) take the scoped concept forward. Same positioning as the repurposing-surface candidates (zileuton, disulfiram, avacopan): the platform's contribution is mechanistic clarity and the published rationale, not the IND.
This positioning matters because it preserves the clean two-track narrative: Open Enzyme as platform builds (a) a strain library you can grow at home, and (b) a discovery engine that surfaces non-fermentable mechanisms for partners to take to clinic. siRNA against URAT1 is the cleanest example of (b) the matrix has surfaced so far.
Comparison with sister exploration vectors¶
| Dimension | Koji chassis | LBP chassis | siRNA / URAT1 (this page) |
|---|---|---|---|
| OE output type | Strain library | Strain library (commercial-pharma sub-track) | Discovery-engine output |
| Manufacturing | Home-fermentable + community-scale | Anaerobic bioreactor; commercial-scale only | Synthetic oligonucleotide chemistry; commercial-pharma only |
| Regulatory path | GRAS food / DSHEA supplement | FDA Live Biotherapeutic Product (BLA) | FDA biologic (BLA — siRNA-class precedent: inclisiran, patisiran) |
| Distribution | Open-source spores; community | Pharmacy / mail-order pharmaceutical | Subcutaneous injection in clinical setting |
| Capital to first commercial dose | $0–500K | $50–200M | $200–500M+ (long-horizon delivery R&D) |
| Time to first commercial dose | Months | 5–8 years | 10+ years (kidney-tropic delivery is the gating R&D) |
| Patient population | Broad gout market, mild-to-moderate | Q141K / refractory / high-severity | Adherence-limited, refractory, hepatic-impaired, hormone-modulated |
| OE platform role | Primary chassis | Peer-track scope page + Phase 2 follow-ups | Discovery-engine output; partner / spinout territory |
| Open-source compatibility | Native — strain library on GitHub | Strain genetics open; manufacturing closed | Mechanism + target + delivery rationale open; clinical IP closed |
The three tracks together represent the chase-every-avenue framing: koji for the broad democratized market, LBPs for the durable-colonization subset, siRNA for the long-horizon "mechanistically cleanest" frontier.
Open Follow-Ups¶
Six in silico Phase 2 follow-ups, no pharma-partner dependency to start. Tracked in multiple redundant surfaces (this page, open-questions.md, computational-experiments.md, index.md, hypotheses/H03-sirna-urat1-thesis.md, and synthesis/ Strategic Reflections Queue).
| ID | Item | Type | Status |
|---|---|---|---|
| P2-1 | Lit scan: kidney-tropic conjugate chemistry state-of-the-art (megalin-binding peptides, CDP nanoparticles, kidney-cortex-selective LNPs, aptamer-siRNA chimeras — design space, current best titers / pharmacokinetics, IP landscape) | Literature review (Opus subagent) | Queued |
| P2-2 | comp-009: URAT1 mRNA structural analysis for siRNA target site selection. Inputs: SLC22A12 transcript variants, secondary-structure prediction (RNAfold), accessibility scoring, conservation across mammalian orthologs for cross-species pharmacology readiness | Computational analysis (Sonnet subagent) | Queued |
| P2-3 | Lit scan: commercial / clinical landscape for kidney-tropic siRNA programs (Alnylam, Arrowhead, Dicerna / Novo Nordisk, Sirnaomics, Calando-successors; non-gout indications and what transfers; partnership / licensing profile) | Literature review (Opus subagent) | Queued |
| P2-4 | Comparative analysis: siRNA vs. small-molecule URAT1 inhibitors (pozdeutinurad / AR882 efficacy, safety, cost, durability, hormone-axis-interaction). Honest assessment of the competitive 5–10 year horizon | Synthesis (Opus subagent or inline) | Queued |
| P2-5 | Falsification card H03: siRNA / URAT1 thesis — full claim, assumption stack, killshot menu, pre-committed thresholds | Hypothesis formalization | Stub committed; full population queued |
| P2-6 | Lit scan: FDA siRNA regulatory path (inclisiran / patisiran precedent, IND-enabling package, ballpark timeline + capital for a kidney-tropic siRNA BLA) | Literature review (Opus subagent) | Queued |
| P3 | Platform-framing reflection (shared with LBP track) — does the discovery-engine track (siRNA / URAT1, kidney-tropic conjugates, Q141K pharmacological chaperones, mRNA-IL-1RA pulse therapy) accumulate enough substance to formally rebrand Open Enzyme as "open-source gout-solving research project" rather than "open-source koji-engineered enzyme library"? | Strategic reflection | Queued, content-triggered; rolled into the existing Strategic Reflections Queue entry in synthesis/ (architecture: synthesis/README.md) |
Limitations of this page¶
- Scope-page, not a deep-dive. The technical depth on conjugate chemistry, target-site selection, and competitive landscape comes from the Phase 2 follow-ups. Until those land, this page is the framing skeleton.
- No wet-lab work proposed by Open Enzyme directly. siRNA wet-lab requires oligonucleotide synthesis facilities, kidney-tropic delivery chemistry capability, and a renal-focused biology lab — none of which the platform has or plans to acquire. This vector advances via partnerships, not in-house wet-lab.
- The competitive timing is honest. Pozdeutinurad's 2026 NDA will define the small-molecule URAT1 inhibitor floor for the next 5–10 years. siRNA's distinctive value is durability + sequence-specificity + hormone-independence, not raw potency or earlier-to-market.
- Kidney-tropic delivery may not converge. All four current research-class delivery approaches (megalin-binding, CDP, LNP, aptamer) are pre-clinical. If none reach first-in-human within 3–5 years, the "kidney-tropic siRNA for gout" vector may be deferred indefinitely. The platform should track delivery-chemistry literature (Phase 2 P2-1) actively to know when to escalate or shelve.
- OE expertise gap. Open Enzyme's center-of-mass is fungal / yeast genetic engineering. Kidney pharmacology, oligonucleotide chemistry, and regulatory siRNA strategy are all outside the in-house competence. Pursuing this vector meaningfully would require either (a) partnering with an Alnylam-style company, (b) recruiting collaborators from the kidney-tropic delivery research community, or © treating this as a pure discovery-engine output where Open Enzyme publishes scope and rationale and steps back.
Cross-References¶
modality-chokepoint-matrix.md— the matrix entry that surfaced this vector as #1 open exploration questiongout-pathophysiology.md§"URAT1 (SLC22A12) — THE REABSORPTION VILLAIN" — URAT1 mechanism background; ~90% urate reabsorption statandrogen-urate-axis.md— testosterone effects on URAT1 (the hormone-axis interaction siRNA bypasses)engineered-lbp-chassis.md— sister peer-track exploration vector (commercial-pharma, durable-colonization angle); same chase-every-avenue framing under the broader gout-solving missionopen-enzyme-vision.md§2.2 (repurposing surface / discovery-engine outputs); §4 (Phase 3 platform-framing reflection note)open-questions.md§"Engineered LBP chassis" parallel; siRNA / URAT1 entry to be added in same section patterncomputational-experiments.mdPlanned Analyses — comp-009 entryhypotheses/H03-sirna-urat1-thesis.md— falsification card stubsynthesis/2026-05-05 Priority Action #3 — the originating action; Strategic Reflections Queue entryopen-source-platform.md§"6. Variant-Agnostic Empirical Head-to-Head" — the principle that governs comp-011's parallel-uricase-variant approach; explicitly does NOT apply to siRNA conjugate-chemistry decisions (GalNAc-analog vs. peptide vs. kidney-tropic LNP) because per-candidate cost is in the $10K+ range — synthetic oligonucleotide chemistry, conjugate formulation, and animal biodistribution work each cost orders of magnitude more than the comp-011 gene-synthesis case. Literature pre-selection burden is justified here; parallel testing is reserved for candidates the literature genuinely cannot rank.